DEXAMETHASON Krka 4 mg/1 mL otopina za injekciju Bosnië en Herzegovina - Kroatisch - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

dexamethason krka 4 mg/1 ml otopina za injekciju

krka farma d.o.o. sarajevo - дексаметазон - otopina za injekciju - 4 mg/1 ml - 1 ml otopine za injekciju sadrži: 4 mg deksametazon fosfata (u obliku deksametazon natrijum fosfata)

GAZYVARO 1000mg/40ml Koncentrat za rastvor za infuziju Montenegro - Kroatisch - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

gazyvaro 1000mg/40ml koncentrat za rastvor za infuziju

"hoffmann-la roche ltd" d.s.d. podgorica - obinutuzumab - koncentrat za rastvor za infuziju - 1000mg/40ml

DEXAMETHASON KRKA 4mg/ml Rastvor za injekciju Montenegro - Kroatisch - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

dexamethason krka 4mg/ml rastvor za injekciju

dio stranog druŠtva "krka d.d. novo mesto" slovenija - predstavniŠtvo podgorica - deksametazon - rastvor za injekciju - 4mg/ml

Tecartus Europese Unie - Kroatisch - EMA (European Medicines Agency)

tecartus

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - limfom, mantel-stanica - antineoplastična sredstva - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).

Carvykti Europese Unie - Kroatisch - EMA (European Medicines Agency)

carvykti

janssen-cilag international nv - ciltacabtagene autoleucel - multipli mijelom - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.